HDCRT Plus Pembrolizumab in Advanced Malignancies
NCT02987166
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
21
Enrollment
OTHER
Sponsor class
Conditions
Solid Tumor
Interventions
RADIATION:
High-Dose Conformal Radiation Therapy
DRUG:
Pembrolizumab
Sponsor
James Larner, MD